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Loss of heterozygosity at chromosome 11 in breast cancer: association of
prognostic factors with genetic alterations
J Gudmundsson, RB Barkardottir, G Eiriksdottir, T Baldursson, A Arason, V Egilsson and S
Ingvarsson
Department ofPathologyv Division ofCell Biology, University and National Hospital ofIceland, Box 1465 IS-121 Revkjavik,
Iceland.
S_mnuary We examined DNA from 116 female and four male breast cancer patients for loss of
heterozygosity (LOH). DNA was analysed by polymerase chain reaction using ten microsatellite markers on
chromosome 11. Three distinct regions of LOH were identified: lIpl5.5, 11q13 and lq22-qter with a LOH
frequency of 19, 23 and 37-43% respectively. The marker DllS%9 showing the highest frequency of LOH
(43%) is located at the II q24.1-q25 region. No previous molecular genetic studies have shown frequent LOH
at the region telomeric to q23 on chromosome 11. Southern analysis revealed that LOH at 1q13 was due to
amplification, whereas LOH at Iq22-qter was due to deletion. LOH at llpl5.5 was associated with paucity
of hormone receptor proteins, high S-phase and positive node status. An association was found between LOH
at I1q13 and positive node status. LOH at the 1q22-qter region correlated with a high S-phase fraction. A
significant association was found between LOH at llpl5 and chromosome regions 17q21 (the BRCAI region)
and 3p.
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The majority (approximately 90%) of breast cancer cases are
considered to be sporadic. Multiple genetic alterations
accumulating in cells result in alterations of normal growth
control. Characterisation of the genes that play a role in this
tumongenic process is a necessary step towards understand-
ing it. Mapping the chromosomal regions that are altered in
breast cancer cells has proven to be a powerful way of
locating these genes. Deletion and gene activation are known
to be the most frequent genetic changes in breast cancer cells.
Chromosomal translocations may also be involved in the
development of breast cancer, as suggested by Lindblom et
al. (1994), who showed that the constitutional llq;22q trans-
location predisposes to breast cancer. Chromosomal regions
that are known to be amplified in breast cancer are 8q (Escot
et al., 1986), 1 1q13 (Varley et al., 1988), 17q (Yokota et al.,
1986) and 20q (Kalliomemi et al., 1994). Regions with fre-
quent LOH in breast cancer are lp (Genuardi et al., 1989),
lq (Chen et al.. 1989), 3p (Eiriksdottir et al., 1995), 6q
(Devilee et al., 1991), Ilpl5 (Ali et al., 1987), 13q (Lundberg
et al.. 1987), 16q (Sato et al., 1990), 17p (Mackay et al.,
1988), 17q and 18q (Cropp et al., 1990).
Chromosome 11 has been shown to possess the Wilms'
tumour 1 gene (WTI) on the p-arm (Madden et al., 1991).
The MEN-I locus has been mapped to the 1lql3 region
(Larsson et al., 1988) and the ataxia telangiectasia (AT) genes
have been mapped to the 1lq22-23 region (Gatti et al.,
1988). Epidemiological studies suggest that heterozygous AT
carriers may be predisposed to cancer (Swift et al., 1991).
The relative risk for breast cancer has been estimated to be
5-fold greater in women carrying the AT gene(s) than in the
normal population. Cytological and LOH studies have des-
cribed aberrations on chromosome 1lq22-q23 in breast
cancer (Ferti-Passantonopoulo et al., 1991; Carter et al.,
1994).
Studies on cancer cell lines (e.g. MCF-7) have shown that
chromosome 11 suppresses tumorigenicity when injected into
cells lacking a normal chromosome 11 (Negrini et al., 1994).
The long arm of chromosome 11 suppresses tumorigenicity
of HeLa cells (Misra and Srivatsan, 1989), suggesting a
tumour-suppressor gene on llq.
In this study we have used a panel of polymorphic mic-
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rosatellite markers to identify and investigate regions show-
ing aberration on chromosome 11.
Materials awd methods
Samnples
Primary breast carcinoma tissue was obtained on the day of
surgery, immediately frozen, and stored at - 80C. Peripheral
blood leucocytes were the source of normal DNA. Salting
out procedure (Miller et al., 1988) and phenol extraction
methods were used to obtain DNA from whole blood and
tumour samples respectively. The ratio of tumour vs normal
cells in the samples was evaluated by histological examina-
tion. Tumours with scores of tumour cells <55% were ex-
cluded from the study. The choice of cut-off level for tumour
cell fraction in the samples was based upon results from our
studies (A Arason, unpublished results) and by Gruis et al.
(1993), who demonstrated by titration experiments that LOH
can be detected in samples with as much as 60% normal
DNA contamination.
PCR analysis ofmicrosatellites
Microsatellite markers used for LOH analysis of
chromosome 11 are listed in Table I. The microsatellite
markers used for chromosome 17 were: TP53 for the 17pl3
region (the p53 gene) and THRA, D17S800, D17S855 and
D17S579 for the 17q21 region (containing the BRCAI gene)
(T Baldursson et al., manuscript in preparation). The
markers used for chromosome 3p are: D3S726, D3S1211,
RIK, PH3H2, D3S1029, D3S1076, D3S1067, D3S1233,
D3S1217, D3S1210 and D3S1101 (Eiriksdottir et al., 1995).
PCR was done with 50 ng of genomic DNA in 25iLl volumes
using DynaZyme DNA polymerase (Finnzymes Oy) at 0.5
units per reaction and the buffer supplied with the
polymerase. Primers were labelled with [y-ATP-32P] (Amer-
sham) using T4-polynucleotide kinase (Amersham). Samples
were subjected to 35 cycles of amplification, consisting of 50 s
at 94°C, 40 s at 55'C and 40 s at 72°C, followed by final
extension for 10min at 72°C. PCR products were separated
on 6.5% acrylamide sequencing gels and exposed for
visualisation by autoradiography on Dupont Cronex-4 film.
Autoradiograms were inspected visually. Any absence orciwo se 11 in bha canoer
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Table I Information about microsatellite markers and results from PCR analysis
NVo. ofpairs No. ofpairs
Distance No. ofpairs Informative with allelic
(cM) Locus Locationa Tipe Referemce examined (%0) imbalance (%)
Gyapay et al. (1994)
Gyapay et al. (1994)
Gyapay et al. (1994)
Polymeropolus et al. (1989)
Brown et al. (1990)
Litt et al. (1989)
Gyapay et al. (1994)
Gyapay et al. (1994)
Gyapay et al. (1994)
Gyapay et al. (1994)
'According to the Genome data base.
significant decrease in the intensity of one allele relative to
the other was considered LOH (see Figure 1).
Southern blot analjsis
Aliquots of 3-10ig of genomic DNA were digested over-
night with a suitable restnrction enzyme according to the
manufacturer's procedure, loaded onto 0.8% agarose gels
and electrophoresed at 35-55 V overnight, transferred to a
Hybond nylon membrane (Amersham) according to standard
protocols (Sambrook et al., 1989). The RFLP probes used in
this study were SS6, FGF3 (llql3.3); STMY1, MMP3
(1lq22.3); MCT 128.1, D1IS144 (1lq22.3-q23); and phi 2-
11-2.2, Dl1S34 (1lq23-qter). A probe for the MOS gene,
HM2A (8ql 1), was used as an internal control for a normal
copy number of alleles. The probes were labelled using a
Megaprime DNA labelling kit (Amersham). Hybridisation
was carried out overnight at 65°C and the filters were washed
at 65°C, 2 x 15min with 2 x SSC, and 2 x 15min with
2 x SSC/0.1% sodium dodecyl sulphate (SDS), followed by a
2 x 25 min stringency wash with 0.2 x SSC.
1175 1187 984 1151
N T N T N T N T
147 bp
145 bp
- 141 bp
139 bp
- 135bp
Figre I Results from PCR analysis with microsatellite marker
DlIS912 of four samples, all exhibiting LOH. N. normal DNA;
T. tumour DNA.
Statistical methods
Chi-square analysis was used to test for association between
the genetic events examined and the clinicopathological
parameters of the patients. The chnicopathological charac-
teristics were categorised as follows: oestrogen receptors
(ER): negative (S 10 fmol mg-1 protein) or positive
(> 10 fmol mg-' protein); progesterone receptors (PgR):
negative ( S25 fmol mg-' protein) or positive
(>25 fmol mg-' protein); histological type: ductal or
lobular; lymph node status: negative or positive; tumour size:
2 cm or >2 cm; age: <50 years or > 50 years; S-phase
fraction, <7% or > 7%; and ploidy: diploid or non-diploid.
All patients were checked for family history of breast cancer.
The family coefficient was categonsed as follows: those who
had at least one first-degree or second-degree relative with
breast cancer or those who had no known relative with
breast cancer. Others were not included in the calcula-
tions.
The chi-square test was also used to assess the relationship
between LOH at chromosome I lq and LOH at
chromosomes 17 and 3p.
Results
PCR analysis
We screened 116 female and four male primary breast
tumours for LOH with ten polymorphic markers on
chromosome 11, seven of them located at the q-arm and
three located at the p-arm. Fifty-three (45%) of the 116
tumours showed LOH with at least one of the ten markers.
Seven tumours (6%) had LOH only at Ilp, 33 tumours
(28%) had LOH only at llq, and 13 tumours (11%) had
LOH at both 1 lq and lp, five of which had lost the whole
chromosome. Three of the four male breast tumours had
LOH at 1 lq and two of them also at lp. The frequency of
LOH for each of the ten markers ranged from 7-43%, being
highest at the most telomeric part of chromosome llq at
43% (DIIS969) and at the llq22 region at 37% (DIIS35
and DlIS927). The lowest frequency of LOH was observed
at the most proximal region on lip (DlIS903).
Figure 2 shows PCR results from nine of the tumours
analysed. Tumours 561, 593 and 1200 are examples where
only the most telomeric region (1 lq24-qter) was lost
(marker Dl1IS925 or more distal markers). Tumours 842,
1030 and 567 only showed aberrations proximal to the
DlIS925 locus at chromosome llq, and the LOH in these
tumours included the 1 1q22 region. Tumours 1071, 1201 and
1121 only had LOH at the lIp region.
Southern analysis
Southern analysis was carried out to distinguish between
amplification and deletions at chromosome 1llq. DNA from
17 of the 46 tumours that showed LOH at lq with mic-
rosatellites was available for Southern hybridisation. We pro-
bed for four different loci: one at 1q13 (FGF3) and three at
llq22-qter (MMP3, DlIS144 and DIIS34). We were not
Dl lS922
Dl lS907
D 1S903
FGF3([NT2)
Dl lS527
D1I S35
D 1IS927
Dl IS925
DIIS912
DIIS%9
lIp15.5
llpl3-ql3
lIpl3-ql3
I lql3.3
I Iql3.5
1 1q22
I 1q22
I lq22.3-q24
I lq25
1 q24.1 -q25
AC repeat
AC repeat
AC repeat
AC repeat
AC repeat
AC repeat
AC repeat
AC repeat
AC repeat
AC repeat
103
106
95
113
110
97
87
105
101
79
90 (87)
88 (83)
74 (78)
84 (74)
103 (94)
76 (78)
75 (86)
87 (83)
88 (87)
58 (73)
17 (19)
11(12)
5 (7)
19 (23)
26 (25)
28 (37)
28 (37)
27 (31)
31 (35)
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able to detect a single amplification with the three probes
that we used at 1 1q22-qter. However. Southern analyses
proved that eight of the ten tumours, available for Southern
analyses and showing LOH with the FGF3 microsatellite
marker, were amplified. The amplification in each sample was
estimated by titration to range from 2- to about 20-fold (data
not shown). Figure 3 shows the pattern of LOH detected by
PCR vs the results of the Southern analysis for the eight
tumours having amplification at 1 Iqi3.3 and the two
tumours that had no amplification. Tumours 1120, 795, 1110.
549, 975. 1216 and 1154 all exhibited the pattern of
amplification at the 11qi3 region and LOH at the more
distal part of chromosome 1 lq. Tumour 981 only had
amplification at llql3 (i.e. no LOH) and tumours 982 and
799 had most likely lost the whole chromosome since all
informative microsatellite markers showed LOH. Figure 4
shows the Southern results for two of the samples
analysed.
and non-diploidy. A significant association was found
between LOH at lip13 (DlIS907) and positive node status
and negative ER and PgR status. A significant association
was found between LOH at 11q13 (FGF3 and DllS527) and
positive node status and also between LOH at 11q24
(Dl S969) and node positive tumours.
The statistical analysis showed a significant association
between LOH at the llq22-qter region and a high S-phase
fraction. The only significant association observed between
LOH and the family coefficient was at 1IqI3.5 (DlIS527).
No association was detected between LOH at any region of
chromosome 11 and tumour size. tumour type or age of the
patients at diagnosis. A significant association was found
between LOH at 17q21 and LOH at l p15. Two LOH
regions at chromosome 11 (1IpIS and llq22-qter) showed
significant association with LOH at chromosome 3p. No
significant association was observed between LOH at
chromosome 17p (p53) and chromosome 11 (Table III).
Statistical analysis
Table II shows the results from the chi-square analysis of
association between LOH at chromosome 11 and clinico-
pathological factors. A statistically significant association was
found between LOH at llp (Dl S922) and positive nodes.
negative ER and PgR receptor status, high S-phase fraction.
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Figure 3 Results from Southern analysis of tumours that
showed LOH for microsatellites. _, allelic imbalance; EDI.
amplification; m. not informative or not done: [Ii1] loss of
heterozygosity: =7 heterozygote; m homozygote, no
amplification. Probes used in Southern analysis are shaded. *
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Figue 4 Results from Southern analysis of two samples, both exhibiting LOH at 1 q22 and amplification at I 1q13. (a) Samples
probed with SS6 (FGF3). (b) Samples probed with STMY1 (MMP3). (c) Samples probed with HM2A (c-MOS) for comparison of
DNA content. N. normal DNA; T. tumour DNA.
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Table H Results from statistical analysis of genetic alteration and clinicopathological factors
ER PgR Tumour Node Tumour Age at S-phase Ploidy Famili
Markers status status type status size diagnosis fraction status coefficient
D1 S922 0.0001*** 0.004** NS 0.012* NS NS 0.0023** 0.023* NS
D1 S907 0.019* 0.0065** NS 0.016* NS NS NS NS NS
D11S903 NS NS NS NS NS NS NS NS NS
FGF3 NS NS NS 0.0092** NS NS NS 0.03* NS
DI IS527 NS NS NS 0.0053** NS NS NS NS 0.025*
DllS35 NS NS NS NS NS NS 0.0086** NS NS
D1lS927 NS NS NS NS NS NS 0.04* NS NS
DI lS925 NS NS NS NS NS NS 0.04* NS NS
D lIS912 NS NS NS NS NS NS 0.018* NS NS
D1 S969 NS NS NS 0.03* NS NS 0.0014** NS NS
*95%, **99%, ***99.9%. NS, not significant. llpl5 (DIIS922 and DI1S907) was associated with negative oestrogen and progesterone
receptor content, positive node status, high S-phase fraction and non-diploid status. 1 1q13 (FGF3 and Dl 1S527) was associated with positive
nodes and (for Dl 1S527) having at least one first-degree or second-degree relative with breast cancer. 1 1q22-qter associated with high S-phase
fraction and Dl 1S969 with node positive breast cancer.
Table In Association of LOH at chromosome 11 with LOH at chromosome 17 and the 3p
region
lIpl5 11qB3 1Iq22-qter
LOH ROH LOH ROH LOH ROH
17pl3 LOH 8 20 8 25 11 22
(p53) ROH 5 38 10 39 17 34
P-value 0.07 0.68 1.00
17q21 LOH 13 10 10 18 12 16
(BRCAI) ROH 4 61 15 63 24 54
P-value 0.000*** 0.08 0.25
3p LOH 11 13 11 20 15 14
region ROH 4 47 13 43 17 41
P-value 0.000*** 0.22 0.04*
The figures denote the number of informative samples that were analysed at the chromosomal
regions. The chi-square test was used to determine significance. LOH, loss of heterozygosity;
ROH. retention of heterozygosity.
Discson
It is well established that chromosome 11 is frequently
altered in human breast cancer. Until now two regions,
lIpl5 and 11q13, have received most attention (Ali et al.,
1987; Varley et al., 1988). The results presented here confirm
that one additional region on chromosome 11 (1 1q22-qter)
is altered in breast cancer (Carter et al., 1994). The regions
showing the highest frequency of LOH were lIp15,
1 1q22-q23.3 and 1 1q24-qter. In some tumours these were
the only regions found to be altered (Figure 2). Frequent
LOH telomeric to 1 1q23 has not been described previously in
breast cancer. Whether the 1lq22-q23.3 and 1lq24-qter
regions are both target regions for deletion or whether one is
only a subregion of the other remains to be shown. A
fine-scale microsatellite mapping in a larger number of
tumour samples could provide information necessary to ans-
wer this question.
We could not detect amplification at the 1lq22-qter
region by Southern analysis. Therefore we conclude that the
LOH detected by the microsatellite markers are deletions.
This region is also frequently found to be deleted in ovarian
cancer (Foulkes et al., 1993).
Mapping of amplifications vs deletions demonstrates that
the use of conventional PCR results alone to draw con-
clusions about deletion or amplification is questionable.
Tumours 1110 and 549 are examples of cases where a clear-
cut boundary between amplification and deletion cannot be
determined from a map of LOH created by PCR analysis
(Figure 3).
Our results from statistical analysis of clinicopathological
variables and LOH at 11p15.5 and 11q13 support previously
published results. A signficant association was found between
LOH at llpl5.5 and llpl3-ql3 (D1IS922 and D1IS907
respectively) and negative hormone receptor status and
positive nodes. LOH at Ip15 (DllS922) was also associated
with high S-phase fraction and non-diploid status. Similar
results regarding nodes and hormone receptors have been
reported by Ali et al. (1987) and Takita et al. (1992). We
found no correlation with LOH at lip and tumour size, age
of onset or tumour type.
Previous studies have shown a significant association
between amplification at 1lq13 and positive nodes (Adnane
et al., 1989), positive oestrogen receptors and shorter life
expectancy of those who were node negative (Borg et al.,
1991). The present results showed no association between
positive hormone receptors and amplification at 11q13. How-
ever, our results showed association between LOH at 1lq13
and node positive breast cancer. LOH detected with the
DlI S527 marker was also associated with having at least one
first-degree or second-degree relative with breast cancer.
Whether that has anything to do with the vicinity of the
MEN-i region, remains to be shown.
In this study the highest frequency of LOH was detected at
1lq22 (markers D11S35 and D1IS927) and 1lq24-qter
(telomeric to the DlIS925 marker). The same regions are
thought to be involved in AT. The AT group A and C
pedigrees show linkage to the llq22-q23.1 region (Gatti et
al., 1988) and a candidate gene that corrects for the radiosen-
sitivity in AT group D fibroblasts has been cloned from the
1 lq23.3-q24 region (Kapp et al., 1992). Epidemiological
studies have suggested that AT carriers are at a 5-fold risk of
breast cancer (Swift et al., 1991). Wooster et al. (1993) found
no evidence of linkage to the AT region in familial breast
cancer. We have found LOH at 1 lq22-qter in breast cancer
cases from a family with a convincing linkage to BRCAJ (J
Gudmundsson et al., unpublished results). Therefore the pos-
sible involvement of the AT region in the development of
breast cancer in members of high risk breast cancer families
is not ruled out. The molecular basis of AT is thought to be
an abnormality of DNA repair (Hanawalt and Painter,
1985). The fact that LOH at 1 Iq22-qter correlates with aChrom1osoni in b ea cancer
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high S-phase fraction raises the question whether the AT
gene might be involved in the control of DNA synthesis.
Determination of the frequency of LOH at chromosome
llq22-qter in AT carriers with breast cancer could be of
help in clarifying that supposition.
The absence of association of LOH at 1 lq22-qter with the
progesterone receptor, which has been mapped to the
llq22-q23 region (Rousseau-Merck et al.. 1987), seems to
be comparable to the absence of correlation between oest-
rogen receptor and LOH at chromosome 6q (Magdelenat et
al., 1994). A possible explanation could be that having one
copy of these hormone receptor genes is sufficient for the
cells and also that a strong selection exists against mutations
in these genes.
A significant correlation has been described by Takita et
al. (1992) and Carter et al. (1994) between LOH at 17pl3
and LOH at chromosome 11 (llpl5 and 1lq22-q23 respec-
tively). Our results showed no significant association between
LOH at chromosome 11 and 17p. On the other hand a highly
significant association was found between LOH at lp15 and
LOH at 17q21 and 3p, which is interesting in our opinion in
view of the location of the BRCAJ gene at 17q21. Eiriksdot-
tir et al. (1995) found LOH at chromosome 3p to be a
significant prognostic variable for overall survival of breast
cancer patients. The significant association between LOH at
llpl5 and 3p could therefore have some prognostic value.
Although only a few samples were examined, the incidence of
LOH at chromosome 1 lq in male breast cancer is of interest.
We think therefore that further investigations at the 1 Iq
region should be made with more samples of male breast
cancer cases.
Chromosome 11 has been shown to suppress malignancy
in cell hybrids. This supports the idea that chromosome 11
includes tumour suppressor gene(s). Introduction of the q-
arm of chromosome 11 into HeLa cells was shown to supp-
ress malignancy (Misra and Srivatsan, 1989). When a whole
chromosome 11 was transferred into an MCF-7 breast cancer
cell line, tumorigenicity was suppressed. Further refinement
of tumour-suppressor gene(s) location implied the possibility
of two genes, at IlplS.5 and llql3-q23 (Negrini et al.,
1994). These conclusions were based upon the frequent
findings of LOH on llpl5.5. Our results suggest that the
1lq23-qter region may be just as likely to contain the supp-
ressor of malignancy. Both of these regions (i.e. llpl5.5 and
llq23-qter) were deleted in a subclone of MCF-7 cells that
still possessed malignancy (Negrini et al., 1994). A tumour
suppressor gene might also be localised to the common
region (1lq22-q23) of these two studies (Negrini et al., 1994
and the present one) because the MCF-7 cells that retained
this region had lower tumorigenicity. The possibility of two
suppressor genes, located at the llq22-q23.3 and q24-qter
region, should therefore not be excluded.
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